newsfilter
← Latest News
GlobeNewswire·

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742 continues to show dose linear pharmacokinetics up to 80mg three-days-on, four-days-off